Prilosec OTC Continues To Gain Share Amid Advertising, Supply Pressures
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble says sales of Prilosec OTC will face difficult year-over-year comparisons in the current quarter, indicating that growth for the heartburn drug may be slowing
You may also be interested in...
GSK Hopes To Energize Tagamet HB By Targeting New Male Audience
GlaxoSmithKline Consumer Healthcare is attempting to reinvigorate its OTC Tagamet heartburn remedy brand with a new marketing and advertising campaign targeting young males
P&G Healthcare Business Has $10 Bil. Potential – CEO Lafley
Procter & Gamble's healthcare unit could generate in excess of $10 bil. annually within a few years, according to CEO A.G. Lafley
P&G Leverages Prilosec OTC, Oral Care Products To Increase Market Leads
Procter & Gamble's Prilosec OTC has garnered nearly a quarter share of the over-the-counter stomach remedy category